Wednesday, July 3, 2013
Immunomedics Inc., of Morris Plains, N.J., reported findings from a Phase Ib study with 90Y-clivatuzumab in patients with metastatic pancreatic cancer who had received at least two prior treatments.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.